XML 72 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Financial Statement Details - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2016
Financial Statement Details [Line Items]        
Depreciation expense $ 16,500 $ 16,300 $ 14,200  
Amortization expense 2,000 1,900    
Impairment of intangible assets 886 681 0  
Net Carrying Amount $ 520 1,390    
Convertible note receivable, discount option, percent 2500.00%      
Convertible note receivable $ 6,879 6,629    
Interest receivable 1,900 1,600    
IPR&D        
Financial Statement Details [Line Items]        
Impairment of intangible assets 900 0 $ 0  
Net Carrying Amount $ 500 1,400    
Riptide Bioscience, Inc.        
Financial Statement Details [Line Items]        
Convertible note receivable       $ 5,000
Interest rate 5.00%      
Milestone payment, payable amount $ 47,000      
Riptide Bioscience, Inc. | Maximum        
Financial Statement Details [Line Items]        
Milestone payment, amount $ 100,000      
Dunkirk Facility | Organized workforce        
Financial Statement Details [Line Items]        
Write off of remaining unamortized organized workforce intangible assets   $ 700